Is DBVT or DNA more undervalued in 2026?

CirclFi compares DBV Technologies S.A. (DBVT) and Ginkgo Bioworks Holdings, Inc. (DNA) using 13 institutional-grade valuation models. DBVT has a Quality of Company score of 4.9/10 while DNA scores 6.1/10.

Which is a better buy — DBVT or DNA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DBVT and DNA valuations compare?

DBVT at $19.10 and DNA at $9.37 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DBVT vs DNA Valuation Comparison 2026 — Intrinsic Value Analysis

DBVT

Biological Products, (No Diagnostic Substances)

DBV Technologies S.A.

Quality

4.9

out of 10

Value Trap

LOW

Price

$19.10

Last close

Models

8/13

Active

DNA

Biological Products, (No Diagnostic Substances)

Ginkgo Bioworks Holdings, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$9.37

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	DBVT Fair Value	DBVT Upside	DNA Fair Value	DNA Upside
Bayesian DCF	Intrinsic	$6.94	-63.7%	$0.13	-98.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$6.78	-64.5%	$3.29	-64.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DBVT vs DNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DBVT vs DNA — Which Stock Is More Undervalued?

DNA scores higher with a 6.1/10 quality rating vs DBVT's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing DBV Technologies S.A. (DBVT) and Ginkgo Bioworks Holdings, Inc. (DNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DBVT currently trades at $19.10 with a QOC of 4.9/10, while DNA trades at $9.37 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).